192 related articles for article (PubMed ID: 35168095)
1. A comprehensive review of varicella-zoster virus, herpes simplex virus and cryptococcal infections associated with sphingosine-1-phosphate receptor modulators in multiple sclerosis patients.
Sharma K; Chaudhary D; Beard K; Srivastava S; Khalid SH; Sriwastava S
Mult Scler Relat Disord; 2022 Mar; 59():103675. PubMed ID: 35168095
[TBL] [Abstract][Full Text] [Related]
2. An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis.
Dumitrescu L; Papathanasiou A; Coclitu C; Garjani A; Evangelou N; Constantinescu CS; Popescu BO; Tanasescu R
Expert Opin Pharmacother; 2023 Mar; 24(4):495-509. PubMed ID: 36946625
[TBL] [Abstract][Full Text] [Related]
3. Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature.
Sriwastava S; Chaudhary D; Srivastava S; Beard K; Bai X; Wen S; Khalid SH; Lisak RP
J Neurol; 2022 Mar; 269(3):1678-1687. PubMed ID: 34800168
[TBL] [Abstract][Full Text] [Related]
4. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis.
Roy R; Alotaibi AA; Freedman MS
CNS Drugs; 2021 Apr; 35(4):385-402. PubMed ID: 33797705
[TBL] [Abstract][Full Text] [Related]
5. Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model.
Corsten CEA; Huygens SA; Versteegh MM; Wokke BHA; Smets I; Smolders J
Mult Scler Relat Disord; 2023 Dec; 80():105100. PubMed ID: 37944195
[TBL] [Abstract][Full Text] [Related]
6. The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination.
Baker D; Forte E; Pryce G; Kang AS; James LK; Giovannoni G; Schmierer K
Mult Scler Relat Disord; 2023 Jan; 69():104425. PubMed ID: 36470168
[TBL] [Abstract][Full Text] [Related]
7. Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects.
Chun J; Giovannoni G; Hunter SF
Drugs; 2021 Feb; 81(2):207-231. PubMed ID: 33289881
[TBL] [Abstract][Full Text] [Related]
8. Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis.
Kihara Y; Chun J
Pharmacol Ther; 2023 Jun; 246():108432. PubMed ID: 37149155
[TBL] [Abstract][Full Text] [Related]
9. Sphingosine-1-phosphate receptor modulators versus interferon beta for the treatment of relapsing-remitting multiple sclerosis: findings from randomized controlled trials.
Yang S; Li X; Wang J; Wang T; Xu Z; Gao H; Chen G
Neurol Sci; 2022 Jun; 43(6):3565-3581. PubMed ID: 35243548
[TBL] [Abstract][Full Text] [Related]
10. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
McGinley MP; Cohen JA
Lancet; 2021 Sep; 398(10306):1184-1194. PubMed ID: 34175020
[TBL] [Abstract][Full Text] [Related]
11. Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis.
Pérez-Jeldres T; Alvarez-Lobos M; Rivera-Nieves J
Drugs; 2021 Jun; 81(9):985-1002. PubMed ID: 33983615
[TBL] [Abstract][Full Text] [Related]
12. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.
Arvin AM; Wolinsky JS; Kappos L; Morris MI; Reder AT; Tornatore C; Gershon A; Gershon M; Levin MJ; Bezuidenhoudt M; Putzki N
JAMA Neurol; 2015 Jan; 72(1):31-9. PubMed ID: 25419615
[TBL] [Abstract][Full Text] [Related]
13. Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data.
Schoedel KA; Kolly C; Gardin A; Neelakantham S; Shakeri-Nejad K
Psychopharmacology (Berl); 2022 Jan; 239(1):1-13. PubMed ID: 34773483
[TBL] [Abstract][Full Text] [Related]
14. Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: A practical review.
Coyle PK; Freedman MS; Cohen BA; Cree BAC; Markowitz CE
Ann Clin Transl Neurol; 2024 Apr; 11(4):842-855. PubMed ID: 38366285
[TBL] [Abstract][Full Text] [Related]
15. Ponesimod for the treatment of relapsing multiple sclerosis.
Baldin E; Lugaresi A
Expert Opin Pharmacother; 2020 Nov; 21(16):1955-1964. PubMed ID: 32808832
[TBL] [Abstract][Full Text] [Related]
16. Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more.
Constantinescu V; Akgün K; Ziemssen T
Expert Opin Drug Metab Toxicol; 2022 Oct; 18(10):675-693. PubMed ID: 36260948
[TBL] [Abstract][Full Text] [Related]
17. Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients.
König C; Kleber M; Reinhardt H; Knop S; Wäsch R; Engelhardt M
Ann Hematol; 2014 Mar; 93(3):479-84. PubMed ID: 24318541
[TBL] [Abstract][Full Text] [Related]
18. Patients' Preferences for Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Based on Clinical Management Considerations: A Choice Experiment.
Keenan A; Whichello C; Le HH; Kern DM; Fernandez GS; Turner V; Das A; Quaife M; Ross AP
Patient; 2024 May; ():. PubMed ID: 38748388
[TBL] [Abstract][Full Text] [Related]
19. Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis.
Chaudhry BZ; Cohen JA; Conway DS
Neurotherapeutics; 2017 Oct; 14(4):859-873. PubMed ID: 28812220
[TBL] [Abstract][Full Text] [Related]
20. The Current Landscape in the Development of Small-molecule Modulators Targeting Sphingosine-1-phosphate Receptors to Treat Neurodegenerative Diseases.
Sankar Kar S; Gharai SR; Sahu SK; Ravichandiran V; Swain SP
Curr Top Med Chem; 2024 Apr; ():. PubMed ID: 38676503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
